巯嘌呤甲基转移酶基因多态性与巯嘌呤类药物治疗关系的研究进展  

Progress in relationship between genetic polymorphism of thiopurine methyltransferase with treatment of thiopurine drugs

作　　者：谢偲[1] 岳丽杰[1] 

机构地区：[1]遵义医学院深圳市儿童医院儿科研究所,广东深圳518026

出　　处：《中国临床药理学杂志》2013年第11期865-868,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金资助项目(30471830);深圳市科技计划重点基金资助项目(201101011)

摘　　要：硫嘌呤甲基转移酶(TPMT)是巯嘌呤类药物代谢的关键酶,也是最具特征性的及具有基因多态性的酶之一。TPMT基因多态性与其酶活性下降有关,携带突变的个体在服用常规剂量的巯嘌呤类药物后,可以导致毒性增加。检测TPMT酶活性或基因型,有助于预测其不良反应发生的风险。本文综述TPMT基因多态性及与巯嘌呤类药物治疗关系的新进展。Abstract： Thiopurine methyhransferase （TPMT） plays an important role in the metabolism of thiopurine drugs, but also has been confirmed as one of the most distinctive enzymes with gene polymorphisms. Some studies have already found the genetic polymorphisms of TPMT affecting its activity and someone who carrying these mutations may increase drug toxicity after taking standarddose of thiopurines. Detecting TPMT genotypes may be helpful to predict the risk of adverse drug reactions. This article reviews the interaction between genetic polymorphism of TPMT and thiopurine drugs to make individual treatment possible.

关 键 词：巯嘌呤甲基转移酶 基因多态性 6-巯基嘌呤 6-硫鸟嘌呤 硫唑嘌呤 

分 类 号：R979.1[医药卫生—药品] R979.5[医药卫生—药学]